Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
IMDX Stock Chart & Stats
$4.00
--
Market closed
$4.00
--
Day’s Range― - ―
52-Week Range$2.33 - $8.51
Previous CloseN/A
VolumeN/A
Average Volume (3M)42.75K
Market Cap
$128.59M
Enterprise Value$103.19M
Total Cash (Recent Filing)$18.69M
Total Debt (Recent Filing)$3.13M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Mar 26, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding32,146,935
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-2.53
Price to Sales (P/S)16.54
P/FCF Ratio-1.47
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue23.44
Enterprise Value/Gross Profit42.83
Enterprise Value/Ebitda-1.76
Forecast
1Y Price Target
$10.50Price Target Upside162.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.8
Revenue Forecast (FY)$3.30M
Bulls Say, Bears Say
Bulls Say
Clinical ValidationAnalyst notes an independent validation showed the company's test delivers patient results within a single day, processes samples individually, and demonstrated strong agreement with a leading sequencing test, supporting clinical reliability.
Commercial Adoption And ReimbursementAnalyst highlights that potential reimbursement for hospitals combined with a major hospital's plan to implement the test in-house could make the offering commercially attractive and encourage institutional uptake.
International Regulatory Progress And RolloutAnalyst indicates the company appears ahead of schedule for European and UK regulatory approvals and is progressing toward a commercial launch, which supports faster international commercialization and planned multi-year clinical site expansion.
Bears Say
FDA Timing RiskAnalyst noted the full FDA submission was slightly behind an earlier target, creating a modest regulatory timing risk that could delay broader commercialization milestones.
Insight Molecular Diagnostics News
IMDX FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was $2.33 and its highest was $8.51 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $128.59M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Mar 26, 2026 which is today.
How were Insight Molecular Diagnostics’s earnings last quarter?
Currently, no data Available
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.24.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,146,935 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in IMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (162.50% Upside)
$10.50 (162.50% Upside)
Hedge Fund Trend
Decreased
By 44.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.71%
12-Months-Change
Fundamentals
Return on Equity
2394.25%
Trailing 12-Months
Asset Growth
-37.43%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
IMDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a generally positive outlook with significant advancements in product development and financial stability. However, the uncertainty due to the government shutdown and slower-than-expected clinical trial enrollment presents challenges.View all IMDX earnings summariesIMDX Stock 12 Month Forecast
Average Price Target
$10.50
▲(162.50% Upside)